OPS/OC/ONDQA/OGD - NIHS

More documents

Recommendations

Info

$Allergies to cross-reactive plant proteins. Latex-fruit ... - NIHS$

添付資料 4-b FDA 後発医薬品審査と米国薬局方 Impact of USP Monographs on the Ollice of Generic Drugs Review Process October 1,2007 Frsnk O. Holcombe, Jr.' Ph.D. Associate Director for Chemistry Ollice of Generic Drugs USP/I\F United States Pharmacopeial Convention . Promote Public Health Through Authoritative Standards and Information . United States Pharmacopeia and National Formulara . Independent . Public Process . Non-Governmental
添付資料 4-b FDA 後発医薬品審査と米国薬局方 United States Pharmacopeia & National Formulary The Official Compendia of Standards Organization . General Notices . Ofiicial Monographs . General Chapters National Formulary USPAIF Monographs ' :*"ililstance Inactive Ingredient (excipients) Drug Product ' :*""T;t t.T,T':::1"-n."u,ar Monographs
Page 1 and 2: 添付資料 3 FDA visit agenda
Page 3 and 4: 添付資料 4-a FDA 後発医
Page 21: 添付資料 4-a FDA 後発医
Page 25 and 26: 添付資料 4-b FDA 後発医
Page 31 and 32: QbR is a System Generic Drug Applic
Page 33 and 34: Janet Woodcock on QbD J. Woodcock.
Page 35 and 36: ISPE PQLI on QbD, Sept. 14, 2007
Page 37 and 38: Overview of QbD Labeled Use Safety
Page 39 and 40: Target Product Quality Profile: Beg
Page 41 and 42: Identifying Critical Material Attri
Page 43 and 44: Critical Quality Attribute • “A
Page 45 and 46: Design Space • Design Space - The
Page 47 and 48: Controlling Input Materials and Man
Page 49 and 50: QbR Questions Provides a Roadmap
Page 51 and 52: How Does QbR Implement QbD Product
Page 53 and 54: How Does QbR Implement QbD Material
Page 55 and 56: How Does QbR Implement QbD Process
Page 57 and 58: Conclusion • The FDA OGD has deve
Page 59 and 60: 2.3.P.2.4 Container Closure System
Page 61 and 62: 添付資料 4-e FDA 新医薬
Page 73 and 74:
添付資料 4-e FDA 新医薬
Page 75 and 76:
Page 77 and 78:
Page 79 and 80:
show all

OPS/OC/ONDQA/OGD - NIHS

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?